Lukas biomedical Inc.
TTPEX:681417.60
TWD
-0.80
(-4.35%)
ISIN
TW0006814007
Return %
Stock
S&P 500
1Y
-35.77
14.20
3Y
-39.71
81.12
5Y
-58.19
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Chao An Liu
- Full Time Employees
- 87
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 16, No. 14, Zhongxiao Road Taipei TP Taiwan 220065
- IPO Date
- Dec 31, 2020
- Website
- lukas-bio.com.tw
- Similar Companies
- Business
- Lukas Biomedical Inc. engages in the development, manufacture, and commercialization of immune cell therapy products and medical equipment primarily focused on cancer treatment. The company’s main products include immune cell therapies such as memory T cell therapy, dendritic cell therapy, and natural killer cell therapy, which form part of its immunocellular therapy portfolio. Additionally, it operates in the wholesale and retail of cosmetics, e-commerce, medical management, pharmaceutical market development, and offers cell reagents as well as brand management and consulting services. Lukas Biomedical also actively conducts Phase II clinical trials targeting liver cancer recurrence and head and neck cancer, leveraging its proprietary immune cell technology. Founded in 2002 and headquartered in New Taipei City, Taiwan, the company has established partnerships with 13 prominent medical institutions in Taiwan and engages in clinical research and regenerative medicine. Recently, Lukas Biomedical entered a strategic cooperation agreement with South Korean company GC Cell Corporation to jointly develop and expand innovative cell therapies, including memory T cell technology, across the Korean and Taiwanese markets, with ambitions for broader international expansion. This collaboration involves joint clinical trials, cross-licensing opportunities, and market development initiatives. Lukas is also advancing its LuLym-T cell therapy through enhanced R&D, clinical advancements, and expansion efforts into Southeast Asia, supported by steady cash flow from its e-commerce and hospital management platforms. The partnership and ongoing clinical trials underscore Lukas Biomedical's commitment to growing its footprint in the immunotherapy and cell therapy sectors, positioning it for long-term growth in the healthcare and biotechnology industries. The company operates primarily in Taiwan but is expanding operations and collaborations into regional markets including Korea and Southeast Asia. It focuses on biotechnology within the pharmaceuticals and healthcare sector, serving cancer patients through innovative immunocellular therapies and supporting medical institutions with specialized immune cell products and medical equipment. Lukas Biomedical continues to invest in clinical trials and product development to strengthen its pipeline and market offerings while enhancing shareholder value through diversification of services and geographic reach. This comprehensive portfolio combined with recent strategic alliances marks Lukas Biomedical as a notable player in the biotech industry specializing in immune cell therapies, cancer treatment innovations, and integrated medical and cosmetic solutions since its founding in 2002.